Executive Leadership

Meet our leaders who guide our purpose to deliver life-changing therapies to patients.

Xiaoping Ye, Ph.D.

Xiaochun Cao

Hao Wu

Zhuan (Helen) Yin

Zengyu (Michael) Wen

Ruibo Chen, M.D.

Jiansong Yang, Ph.D.

Joined Tigermed on February 2020, PhD in University of Sheffield on Pharmacokinetic. Founder and General Manager of Mosim since 2015, deep expertise in innovative drug, clinical development strategy, clinical trial design. 

Xia Chen, Ph.D.

Dr. Xia Chen holds a Doctor of Medicine in Clinical Medicine from Peking Union Medical College and a Doctor degree in Clinical Pharmacology from Leiden University in the Netherlands. She also holds a Master’s degree in Quantitative Pharmacology from the University of Manchester United Kingdom. Prior to joining Tigermed, she has held critical positions including Associate Professor at Clinical Pharmacology Research Center of Peking Union Medical College, Professor of Clinical Pharmacology at Beijing Tiantan Hospital, and Clinical Reviewer at Center for Drug Evaluation (CDE) of NMPA, with 15 years of clinical R&D experience in hospitals and rich academic research experience.

Yunjie(Shelly) Gong

Over 20-year clinical trial experiences, including 9 years in Shanghai Roche to involve project management and monitor activities; meanwhile to responsible for an international multi-center trial as China Local Project Leader. 3-year working experiences as QA manager working with global QA focusing on trial audit in China.

Over 10-year experiences at Tigermed of quality assurance on clinical trial related activities including QMS, auditing as well as GCP training.

Yifei Peng

Fully responsible for medical device related services under Tigermed. Engaged in management in biopharmaceutical R&D and production, pharmaceutical product investment management, medical device registration, pharmaceutical and medical device clinical trial field in Chinese and foreign companies, with a deep understanding of Chinese pharmaceutical product transformation, medical device clinical trial management and registration. Master of Biochemistry from East China Normal University, licensed pharmacist, special expert of China Medical Device Industry Association Clinical Trial Branch. Nearly 20 years of practical experience in the pharmaceutical field.

Tianrong Ji, M.D.

Tianrong Ji, M.D, graduated from Peking Union Medical College, Chinese Academy of Medical Sciences in 1994 and has worked at Peking Union Medical College Hospital, Xi’an Janssen, Roche, Baxter, Fresenius-Kabi etc. She joined Tigermed in July 2014, served as the General Manager of TigerYeah Investment, Vice President and Head of Tigermed Investment Bussiness Unit and has more than twenty years of experience in clinical medicine, fund management and corporate M&A.

Chengcheng Yang

Ms. Chengcheng Yang (Grace), MBA, Zhejiang University. Before joining Tigermed, Ms. Chengcheng Yang worked in PricewaterhouseCoopers, Xizi Otis Company ltd, Xizi Group, Baida Group, Shuanglin Biotechnology Company, Zhejiang United Investment Group Co. ltd. (ZUIG) acting the roles as senior auditor, CFO, Executive Director, Managing Director, etc. She is familiar with China, Hong Kong and International Accounting Standards, specializing in the area of corporate finance, taxation, internal control and operational management with over 20 years’ experience in financial management, investment, financing and capital operation of listed companies. 

Alan Liu

LLM International Business Law from Erasmus University Rotterdam and LLB from Southwest University of Political Science and Law. Before joining Tigermed, Mr. Liu worked for Huawei, Dahua Technology, Alibaba and other large listed companies. He has been conducting legal compliance work and living overseas for nearly 10 years, managing various complex litigations, tax cases and other disputes with a scale of hundreds of millions of dollars. With nearly 20 years of overseas and international legal and compliance management experience and team management experience, he has in-depth practical exploration and accumulation in building global compliance platforms, forming and operating compliance committees, building compliance systems for export control, data security, tax, employment, ESG, etc.